Conditions: Acute Coronary Syndrome
Keywords: Atherosclerosis Heart disease Cardiovascular disease Lp-PLA2 inhibitor The TIMI Study Group Coronary Heart Disease (CHD) Acute Coronary Syndrome (ACS)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13026
Healthy volunteers: no

Brief summary:
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

Detailed description:
Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, 6 months and every 6 months until the end of the study.

Arms:
arm 1: Single daily oral tablet arm 2: Single daily oral tablet

Interventions: intervention 1: Darapladib 160 mg intervention 2: Placebo intervention 3: Standard Therapy
Intervention descriptions: intervention 1: Lp-PLA2 inhibitor intervention 2: Placebo administered intervention 3: Guideline mandated therapy for individual's condition

Protocol document: